 |
1 CNAG (Coordinator, Spain) Marc A. Marti-Renom Centre Nacional d’Anàlisis Genòmic (CNAG) |
 |
2 EMBL (Germany) Matthias Wilmanns EMBL-Hamburg |
 |
3 GSK (Spain) LLuís Ballell GlaxoSmithKline Tres Cantos Medicines Development Centre (GSK TCMDC) |
 |
4 IPBS (France) Olivier Neyrolles Institut de Pharmacologie et de Biologie Structurale/CNRS (IPBS/CNRS) |
 |
5 IP (France) Brigitte Gicquel Institut Pasteur |
-
The GeMoA consortium, composed by four academic research groups and one company from three European countries are joining efforts with the broad aim of integrating computational and experimental approaches into an innovative platform for genome-wide characterization of the mechanism-of-action for selected chemical compounds with activity against Mycobacterium tuberculosis.
This site is powered by WordPress. Theme
inspired by codium-extend.